K
Karl V. Clemons
Researcher at Stanford University
Publications - 203
Citations - 7922
Karl V. Clemons is an academic researcher from Stanford University. The author has contributed to research in topics: Aspergillosis & Aspergillus fumigatus. The author has an hindex of 48, co-authored 203 publications receiving 7412 citations. Previous affiliations of Karl V. Clemons include Santa Clara Valley Medical Center & Western Galilee Hospital.
Papers
More filters
Journal ArticleDOI
Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth
James Kim,Jean Y. Tang,Jean Y. Tang,Ruoyu Gong,Jynho Kim,John J. Lee,Karl V. Clemons,Curtis R. Chong,Kris S. Chang,Mark Fereshteh,Dale R. Gardner,Tannishtha Reya,Jun O. Liu,Ervin H. Epstein,David A. Stevens,Philip A. Beachy +15 more
TL;DR: Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.
Journal ArticleDOI
Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea
TL;DR: The results indicate that there is a correlation between the Candida groups and antifungal susceptibility and those strains previously designated C. albicansgenotype D are in fact C. dubliniensis.
Journal ArticleDOI
Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility.
TL;DR: Basic science, clinical and experimental information about C. parapsilosis is summarized and its virulence appears associated with a capacity to produce biofilm and production of phospholipase and aspartyl protease.
Journal ArticleDOI
Genetic Characterization of Pathogenic Saccharomyces Cerevisiae Isolates
TL;DR: The ability to grow at 42 degrees is shown to be polygenic with primarily additive effects between loci, a property that can be considered a virulence trait and may help explain the presence of these isolates in human hosts.
Journal ArticleDOI
Comparative Efficacies of Conventional Amphotericin B, Liposomal Amphotericin B (AmBisome), Caspofungin, Micafungin, and Voriconazole Alone and in Combination against Experimental Murine Central Nervous System Aspergillosis
Karl V. Clemons,Karl V. Clemons,Marife Espiritu,Rachana Parmar,David A. Stevens,David A. Stevens +5 more
TL;DR: Results indicate that AmBi in combination with VCZ may be superior for treatment of CNS aspergillosis; combinations of AmBi and MICA or CAS were not antagonistic and may have a slight benefit.